Non-metastatic NSCLC and other thoracic malignancies
Invited discussant abstracts 1179PD and 1508PD
Date
10 Oct 2016Session
Non-metastatic NSCLC and other thoracic malignanciesPresenters
Jens SoerensenAuthors
J.B. SoerensenAuthor affiliations
- Department Of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 - Copenhagen/DK
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3259 - Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
Presenter: Patrick Forde
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
3823 - Multi-centre randomized controlled study comparing adjuvant vs neo-adjuvant chemotherapy with docetaxel plus carboplatin in resectable stage IB to IIIA NSCLC: final results of CSLC0501
Presenter: Yi-Long Wu
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Invited discussant LBA41 and abstract 1178O
Presenter: Paul Baas
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
3894 - Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)
Presenter: Taofeek Owonikoko
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
4152 - Small cell lung carcinoma harbors targetable alterations including MYCL1 fusions responding to aurora kinase inhibitor
Presenter: Siraj Ali
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Invited discussant abstracts 1423O and 1424O
Presenter: Pilar Garrido Lopez
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
4203 - Low dose CT scan screening versus empiric surveillance in asbestos exposed subjects: Update of ATOM 002 study
Presenter: Gianpiero Fasola
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2337 - Patient-reported outcomes (PROs) and impact of lactate dehydrogenase (LDH) levels on outcomes in a phase 3 trial (NGR015) with best investigator choice (BIC) plus or minus NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
Presenter: Vanesa Gregorc
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3008 - Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
Presenter: Lecia Sequist
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2926 - Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC)
Presenter: Martin Reck
Session: Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.